TrialNature cancer2024

Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial.

Kaiwen Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.